
SBC Medical's third quarter revenue rose 35% to $59 million, net income attributable to the company rose 22% to $16 million and adjusted EBITDA rose 66% to $28 million, helped by service fee revisions and new clinics.
Ticker: SBC
SBC Medical Group Holdings (SBC), which provides management services to medical clinics in Japan and abroad, reported results for the three months ended 30 September 2026 in a release filed with the SEC on 13 November 2026. Revenue growth came from higher management services revenue, including service fee structure revisions announced in August, and from the consolidation of Waqoo.
The key numbers (quarter ended 30 September 2026)
Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
Total revenues | $58.6 million | $43.4 million | +35% |
Gross profit | $42.2 million | $30.6 million | +37.8% |
Income from operations | $26.4 million | $15.9 million | +66% |
Net income attributable to SBC Medical | $15.7 million | $12.8 million | +22% |
Net income margin | 27% | 30% | Down 3 points |
Adjusted EBITDA | $27.6 million | $16.6 million | +66% |
Adjusted EBITDA margin | 47% | 38% | Up 9 points |
Basic and diluted EPS | $0.15 | $0.12 | +25% |
The operating margin was 45%. Income tax expense was $9.4 million, against $5.7 million a year earlier.
Clinic network
The clinics SBC Medical supports kept growing. At 30 September 2026 the network had 293 locations, up 36 from a year earlier. Patient visits over the trailing twelve months totalled 7.06 million, up 9%, and average spend per visit was $290, up 4%.
Cash
Net cash provided by operating activities was $50 million for the first nine months of 2026. At 30 September 2026 the company held $198 million in cash and cash equivalents and $154 million in net cash. It bought back no shares in the first nine months of 2026.
"The third quarter of 2026 marked a strong reacceleration in SBC Medical's growth," said chairman and CEO Yoshiyuki Aikawa. He said the company is investing in AI, including a proprietary local large language model infrastructure, and developing an in-house DNA methylation test to estimate biological age for its Longevity business.
Nine months so far
For the first nine months of 2026, total revenues rose 13% to $151 million from $134 million. Net income attributable to SBC Medical rose 2% to $38 million, adjusted EBITDA rose 17% to $66 million and basic EPS was $0.37, against $0.36.
Source: SBC Medical Group Holdings third quarter 2026 earnings release, filed with the SEC on 13 November 2026, SEC Form 8-K Exhibit 99.1: https://www.sec.gov/Archives/edgar/data/1930313/000119312526459242/sbc-ex99_1.htm
Full call transcript
Prepared remarks from the company's official recording of its third quarter 2026 earnings call, published on the SBC Medical Group Holdings YouTube channel on 13 November 2026 (https://www.youtube.com/watch?v=QUdc5Mm6dQg). The recording does not name the speaker and does not include the question and answer session.
Speaker: Thank you for taking the time to join our conference call today. I will now walk you through our results for the third quarter of fiscal 2026, an update on our business strategy and our capital and IR.
If I had to sum up this quarter in a single sentence, it is the quarter in which SBC's growth clearly re-accelerated. Revenue rose 35% year on year, income from operations grew 66%, and our adjusted EBITDA margin reached 47%. Growth and profitability are improving in tandem, exactly the operating leverage we have been building toward, and a clear demonstration of the strength of our highly profitable MSO model.
Let me begin with the clinic highlights, which demonstrate the underlying strength of our business. For the first nine months of the year, same clinic revenue reached $836 million, up 7% year on year, continuing its steady growth. What is particularly encouraging is that our growth is being driven by both more customers and higher spend per visit, rising together.
Over the trailing 12 months, we recorded 7.06 million customer visits, up 9% year on year, and 2.26 million unique customers, up 10%. At the same time, average spend per visit increased 4% to $290. Our clinic network also expanded by 36 locations year on year, reaching 293 locations. In short, our existing clinics are growing stronger while our network continues to expand, a powerful combination for sustainable growth.
Next, our financial highlights, third quarter revenue was $59 million, up 35% year on year. Income from operations was $26 million, up 66%. Adjusted EBITDA was $28 million, also up 66%. And our adjusted EBITDA margin reached 47%, an improvement of nine points year on year. Basic EPS was $0.15, up 25%. EBITDA grew far faster than revenue, and our operating margin expanded from 37% to 45% year on year. This is the operating leverage built into our MSO model. We grow not simply by adding clinics, but by raising the productivity and the fees per clinic at the same time.
In the third quarter, we delivered strong revenue and profit growth, reflecting the continued strength of our MSO business model. Revenue increased by $15.2 million year on year, driven by three name factors. First, management services revenue rose 73% year on year, reflecting the service fee revisions we announced in August alongside our second quarter results, together with lower promotional costs in our points business.
Second, rental revenue grew on the back of medical equipment installed at newly opened clinics. And third, the newly consolidated Waqoo segment contributed $5.6 million in revenue. On the profit side, net income attributable to SBC Medical increased 22% year on year, supported by strong growth in our core business.
Now to our business strategy update. Our long-term vision is unchanged, which is to become the name that comes to mind when people think of longevity, living young and vigorous for as long as possible. What is new this quarter is that we are putting a concrete roadmap behind that vision, with initiatives planned in stages through 2028.
Longevity requires a complete cycle, which is diagnosis, personalized treatment, intervention, and verification of results. One of the hardest parts of building that cycle is establishing the medical infrastructure to actually deliver treatment, meaning licensed clinics staffed by doctors and nurses at scale. SBC already has that infrastructure. Our medical network spans 293 locations, covering both appearance-based and function-based care, including AGA, dentistry, orthopedics, ophthalmology, fertility treatment, and regenerative medicine.
Starting in November 2026, we will begin developing our own blood biomarker testing program, with the aim of eventually expanding it across our clinic network. Over time, we believe this initiative has the potential to generate recurring revenue while building a valuable foundation of longitudinal health data. In 2027, we aim to establish a longevity center, together with an online coaching and tracking platform.
Looking further ahead to 2027 and 2028, we plan to develop AI-generated, doctor-verified treatment protocols and explore opportunities to expand our longevity services into the United States through OrangeTwist, as well as Southeast Asia. By combining the medical infrastructure we already have with new diagnostic capabilities and AI, we aim to build a differentiated and difficult-to-replicate position in the longevity market.
As part of step one, diagnostics, we have begun in-house development of a DNA methylation test to estimate biological age, drawing on the research and technology base our Waqoo group has built in regenerative medicine. Unlike our underlying DNA sequence, DNA methylation can change with lifestyle and environment, making it a promising way to track changes in biological age over time and potentially assess the impact of interventions.
Our development rests on three pillars, which are organ-by-organ mapping of biological age, research into non-invasive measurement methods that do not require a blood draw, and data specific to Japan, one of the most aged societies in the world. The goal is straightforward but powerful, to make both biological age and the effect of treatment visible, and to turn that into data-driven, personalized care.
Next, our AI strategy. We are building our own local large-language model foundation that allows us to use patient data safely. Running our own local LLM does two things. First, it lets us develop proprietary features from SBC's unique clinical and customer data that a general purpose AI cannot easily match. And second, it decouples our inference cost from Cloud API pricing, improving the economics.
On this foundation, we are developing six AI features spanning cost, risk, and revenue. On cost, these include voice-driven automatic charting designed to draft a medical record in about one second, returning time from doctors and nurses to patients, and AI shift scheduling aimed at optimizing staffing across our medical network of 293 locations. On risk, we are developing AI monitoring of our clinical systems and data access. And on revenue, the features include a clinic promotion planner, a treatment plan recommendation engine that draws on 26 years of case data to raise spend per visit, and personalized recommendations for each customer to lift lifetime value.
We have also entered a capital and business alliance with Atomic Software, the provider of Medical Force, one of Japan's largest operating platforms for self-pay clinics, adopted by more than 800 clinics with a 99.2% retention rate. The system integrates reservations, electronic charts, payments, customer management, and analytics in a way purpose-built for self-pay medicine, and it is currently used at one of our clinics, Hadano Aozora Clinic.
Together, we plan to create value in three steps, which are co-developing AI features, implementing them in our own systems, and extending them to new brands and new formats. Our goal is to build a more efficient, more standardized operating base that improves the profitability of existing clinics and shortens the ramp-up time for new openings, strengthening the earnings power of our scalable MSO platform as the business expands.
Our brand strength is also earning outside recognition. In Newsweek's World's Best Hospitals and Clinics for Medical Tourism 2027, Shonan Beauty Clinic was selected in two plastic surgery categories, liposuction and breast augmentation, each among the top 75 facilities in the world. We believe this reflects the trust we have built in the medical community. In 2025, doctors from our group presented research at 28 medical conferences in Japan and abroad, with a total of 75 physician appearances. We also offer multilingual support to meet growing inbound demand. We intend to leverage this international recognition to raise our brand awareness overseas and further accelerate our growth.
Finally, our capital and IR. Our basic policy is unchanged, which is to pursue EPS growth and a normalization of our valuation in parallel, and so to enhance shareholder value over the medium to long term. On liquidity and recognition, we are making steady progress. Average daily trading value in October was approximately $1 million, about 4.1 times the level this past July.
The number of our beneficial shareholders reached 7,300 as of October 2026, representing a 1.6 times increase since July 2026. And during this year, through October, we have held 183 one-on-one investor meetings and participated in 22 IR conferences. We recognize that SBC's recognition in the capital markets, particularly in the United States, still has room to grow, and we will keep up this active engagement, encouraging a more diverse investor base, deeper liquidity, and a share price that properly reflects our medium term to long term corporate value.
Let me close with why we are confident in SBC's trajectory. We combine three things that are not often found together in one company, namely high growth, high and rising margins, and a net cash balance sheet that funds its own expansion. Our priorities are clear, which is to drive sustained EPS growth and earn a valuation that properly reflects our medium term to long term potential. Together, these will support lasting shareholder value creation. We hope you will look forward to what lies ahead for SBC. That concludes my remarks. Thank you very much for your attention.
Comments
Log in or sign up to join the conversation.